Navigation Links
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Date:9/18/2007

TOKYO, September 18 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally acting, non-opioid, analgesic, has completed a Phase II proof of principle trial for the treatment of fibromyalgia syndrome (FMS).

The trial, a multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study, investigated the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects. In total, the trial enrolled 103 patients across 18 centres in the UK and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire (FIQ) score, between active and placebo, after 4 weeks of treatment.

Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. However statistical significance in FIQ was achieved at the 1 week time point and positive trends were seen throughout the study. In addition statistically significant measures in other efficacy assessments such as the Short Form McGill Pain Questionnaire and the Fibromyalgia Health Assessment Questionnaire (FHAQ) were seen at early time points. On balance it is concluded that AD 337 has some potential in the treatment of fibromyalgia syndrome.

AD 337 was well tolerated and there were no clinically significant changes in vital signs, biochemistry, haematology and cardiovascular parameters.

Commenting on these results Shinichi Tamura, CEO, said "This proof of principle study with an unoptimised formulation and dosing schedule and limited to four weeks in duration has demonstrated a degree of activity. Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications."

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
(Date:7/31/2014)... Held at the Stanford Cancer Center, ... of the disease and its treatment. Survivors will find ... well as updates on the state-of-the-art with respect to ... for organizing this educational opportunity,” says KCA CEO Bill ... her colleagues have put together a program that balances ...
(Date:7/31/2014)... , July 31, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 4:30 p.m. ...
(Date:7/30/2014)... LA JOLLA, Calif. , July 30, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery and ... it will report financial results and highlights for the ... 2014, after the U.S. financial markets close. ... on Wednesday, August 6, 2014, at 5:00 pm Eastern ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... aims to reach five million in five years, ... DGX ), the nation,s leading provider of diagnostic,testing information ... designed to help increase compliance with take-home colorectal,screening tests. ... Have,the Guts?," the campaign aims to break down barriers ...
... To Be Held Tuesday, April 1, 2008 At 10:00 a.m. Eastern ... ... March 31 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reported ... highlights., (Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO ), "2007 was a ...
... ... 31 Cephalon, Inc.,(Nasdaq: CEPH ) has scheduled its regular quarterly earnings conference call,covering first ... ... Q1 2008 results will be distributed by PRNewswire 4:50 p.m. EDT To ...
Cached Biology Technology:Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 2Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 3Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 2Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 3Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 5Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 6Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 7Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 8Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 9Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 10
(Date:7/31/2014)... same week that the U.S. surgeon general issued a ... at Montana State University published a paper breaking new ... every cell responds when exposed to ultraviolet (UV) ... damage by the UV rays found in sunlight. This ... degenerative eye diseases. , "Our paper advances foundational ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
(Date:7/30/2014)... is paving the way for a breakthrough that ... troops exposed to poisonous chemicalsparticularly those in pesticides ... the current issue of the journal ChemBioChem ... are compounds commonly used in pesticides and warfare ... School of Engineering Associate Professor of Chemical and ...
Breaking Biology News(10 mins):New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2
... The death of insulin-producing beta cells in the pancreas ... Texas now have discovered a new way that these cells ... other pancreatic cells. "Our study shows that neighboring cells ... This was an unexpected finding," said Franco Folli, M.D., Ph.D., ...
... (NIFA) has awarded a consortium of land-grant institutions in ... Coordinated Agricultural Grant to study the effects of climate ... announcement, Paul Winistorfer, dean of the College of Natural ... climate change mitigation and adaptation as it relates to ...
... to increased well-being in adulthood, new research finds. ... childhood and mental health problems, but little research has examined ... time, researchers from the University of Cambridge and the MRC ... between a positive adolescence and well-being in midlife. Using ...
Cached Biology News:Scientists find a new way insulin-producing cells die 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 3Virginia Tech shares in grant to study effects of climate change on southern pine forests 4Happy children make happy adults 2
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning ...
...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: